Multi-target Pharmacology: Possibilities and Limitations of the "skeleton Key Approach" from a Medicinal Chemist Perspective

Overview

Journal Front Pharmacol

Date 2015 Oct 7

PMID 26441661

Citations 119

Authors

Alan Talevi

Affiliations

Soon will be listed here.

Abstract

Multi-target drugs have raised considerable interest in the last decade owing to their advantages in the treatment of complex diseases and health conditions linked to drug resistance issues. Prospective drug repositioning to treat comorbid conditions is an additional, overlooked application of multi-target ligands. While medicinal chemists usually rely on some version of the lock and key paradigm to design novel therapeutics, modern pharmacology recognizes that the mid- and long-term effects of a given drug on a biological system may depend not only on the specific ligand-target recognition events but also on the influence of the repeated administration of a drug on the cell gene signature. The design of multi-target agents usually imposes challenging restrictions on the topology or flexibility of the candidate drugs, which are briefly discussed in the present article. Finally, computational strategies to approach the identification of novel multi-target agents are overviewed.

Citing Articles

A review on pyrimidine-based pharmacophore as a template for the development of hybrid drugs with anticancer potential.

Sharma S, Babu M, Kumar R, Singh T, Dwivedi A, Ahmad G Mol Divers. 2025; .

PMID: 39937329 DOI: 10.1007/s11030-025-11112-x.

Discovery of intermolecular cascade annulation for dihydrobenzo[][1,8]naphthyridine-ylidene-pyrrolidinetriones.

Luo W, Zheng X, Lin H, Fu L, Long L, Yu D Chem Sci. 2025; 16(9):4119-4126.

PMID: 39906387 PMC: 11788672. DOI: 10.1039/d4sc07999j.

Mpox virus (MPXV): comprehensive analysis of pandemic risks, pathophysiology, treatments, and mRNA vaccine development.

Eslamkhah S, Aslan E, Yavas C, Akcali N, Batur L, Abuaisha A Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39777535 DOI: 10.1007/s00210-024-03649-9.

Unveiling the Anticancer Potential of a New Ciprofloxacin-Chalcone Hybrid as an Inhibitor of Topoisomerases I & II and Apoptotic Inducer.

Ali D, Aziz H, Brase S, Al Bahir A, Alkhammash A, Abuo-Rahma G Molecules. 2024; 29(22).

PMID: 39598770 PMC: 11596536. DOI: 10.3390/molecules29225382.

The Dawn till Dusk of phytopharmaceuticals.

Tiwari R, Mishra S, Chauhan A, Gulati P, Dhobi M Saudi Pharm J. 2024; 32(11):102185.

PMID: 39435370 PMC: 11491947. DOI: 10.1016/j.jsps.2024.102185.

References

Catterall W . From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron. 2000; 26(1):13-25. DOI: 10.1016/s0896-6273(00)81133-2. View

Bosetti F, Weerasinghe G, Rosenberger T, Rapoport S . Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J Neurochem. 2003; 85(3):690-6. DOI: 10.1046/j.1471-4159.2003.01701.x. View

Roth B, Sheffler D, Kroeze W . Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov. 2004; 3(4):353-9. DOI: 10.1038/nrd1346. View

Morphy R, Kay C, Rankovic Z . From magic bullets to designed multiple ligands. Drug Discov Today. 2004; 9(15):641-51. DOI: 10.1016/S1359-6446(04)03163-0. View

Ashburn T, Thor K . Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004; 3(8):673-83. DOI: 10.1038/nrd1468. View

Ghelardoni S, Tomita Y, Bell J, Rapoport S, Bosetti F . Chronic carbamazepine selectively downregulates cytosolic phospholipase A2 expression and cyclooxygenase activity in rat brain. Biol Psychiatry. 2004; 56(4):248-54. DOI: 10.1016/j.biopsych.2004.05.012. View

Benaim G, Sanders J, Garcia-Marchan Y, Colina C, Lira R, Caldera A . Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with posaconazole. J Med Chem. 2006; 49(3):892-9. DOI: 10.1021/jm050691f. View

Keller T, Pichota A, Yin Z . A practical view of 'druggability'. Curr Opin Chem Biol. 2006; 10(4):357-61. DOI: 10.1016/j.cbpa.2006.06.014. View

Kwan P, Brodie M . Combination therapy in epilepsy: when and what to use. Drugs. 2006; 66(14):1817-29. DOI: 10.2165/00003495-200666140-00004. View

10.

Hornberg J, Bruggeman F, Bakker B, Westerhoff H . Metabolic control analysis to identify optimal drug targets. Prog Drug Res. 2007; 64:171, 173-89. DOI: 10.1007/978-3-7643-7567-6_7. View

11.

Zimmermann G, Lehar J, Keith C . Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today. 2007; 12(1-2):34-42. DOI: 10.1016/j.drudis.2006.11.008. View

12.

Cheng A, Coleman R, Smyth K, Cao Q, Soulard P, Caffrey D . Structure-based maximal affinity model predicts small-molecule druggability. Nat Biotechnol. 2007; 25(1):71-5. DOI: 10.1038/nbt1273. View

13.

Yildirim M, Goh K, Cusick M, Barabasi A, Vidal M . Drug-target network. Nat Biotechnol. 2007; 25(10):1119-26. DOI: 10.1038/nbt1338. View

14.

Bourgeois B . Broader is better: the ranks of broad-spectrum antiepileptic drugs are growing. Neurology. 2007; 69(18):1734-6. DOI: 10.1212/01.wnl.0000279587.05302.37. View

15.

Wong E, Nikam S, Shahid M . Multi- and single-target agents for major psychiatric diseases: therapeutic opportunities and challenges. Curr Opin Investig Drugs. 2008; 9(1):28-36. View

16.

Petrelli A, Giordano S . From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage. Curr Med Chem. 2008; 15(5):422-32. DOI: 10.2174/092986708783503212. View

17.

Kaminski R, Matagne A, Patsalos P, Klitgaard H . Benefit of combination therapy in epilepsy: a review of the preclinical evidence with levetiracetam. Epilepsia. 2008; 50(3):387-97. DOI: 10.1111/j.1528-1167.2008.01713.x. View

18.

Hopkins A . Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008; 4(11):682-90. DOI: 10.1038/nchembio.118. View

19.

Bianchi M, Pathmanathan J, Cash S . From ion channels to complex networks: magic bullet versus magic shotgun approaches to anticonvulsant pharmacotherapy. Med Hypotheses. 2008; 72(3):297-305. DOI: 10.1016/j.mehy.2008.09.049. View

20.

Petrelli A, Valabrega G . Multitarget drugs: the present and the future of cancer therapy. Expert Opin Pharmacother. 2009; 10(4):589-600. DOI: 10.1517/14656560902781907. View